Cover Image
Market Research Report

Generics in North America

Published by MarketLine Product code 353041
Published Content info 34 Pages
Immediate Delivery Available
Price
Back to Top
Generics in North America
Published: January 4, 2016 Content info: 34 Pages
Description

Generics in North America industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the North America generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

  • For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The North American generics market is expected to generate total revenues of $105.4bn in 2015, representing a compound annual growth rate (CAGR) of 6.4% between 2011 and 2015.
  • Market consumption volume is forecast to reach a total of 88.7 % of total pharma volume in 2015.
  • The North American marketed is dominated by the US, which accounts for nearly 90% of the market's revenues.

Features

  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in North America
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in North America
  • Leading company profiles reveal details of key generics market players' global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the North America generics market with five year forecasts by both value and volume
  • Macroeconomic indicators provide insight into general trends within the North America economy

Key Questions Answered

  • What was the size of the North America generics market by value in 2015?
  • What will be the size of the North America generics market in 2020?
  • What factors are affecting the strength of competition in the North America generics market?
  • How has the market performed over the last five years?
  • How large is North America's generics market in relation to its regional counterparts?
Table of Contents
Product Code: OHME5132

Table of Contents

Executive Summary

  • Market value
  • Market value forecast
  • Market volume
  • Market volume forecast
  • Geography segmentation
  • Market rivalry

Market Overview

  • Market definition
  • Market analysis

Market Data

  • Market value
  • Market volume

Market Segmentation

  • Geography segmentation

Market Outlook

  • Market value forecast
  • Market volume forecast

Five Forces Analysis

  • Summary
  • Buyer power
  • Supplier power
  • New entrants
  • Threat of substitutes
  • Degree of rivalry

Leading Companies

  • Allergan plc
  • Mylan Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Limited

Methodology

  • Industry associations
  • Related MarketLine research

Appendix

  • About MarketLine

List of Tables

  • Table 1: North America generics market value: $ billion, 2011-15(e)
  • Table 2: North America generics market volume: % of total pharma volume, 2011-15(e)
  • Table 3: North America generics market geography segmentation: $ billion, 2015(e)
  • Table 4: North America generics market value forecast: $ billion, 2015-20
  • Table 5: North America generics market volume forecast: % of total pharma volume, 2015-20
  • Table 6: Allergan plc: key facts
  • Table 7: Allergan plc: key financials ($)
  • Table 8: Allergan plc: key financial ratios
  • Table 9: Mylan Inc.: key facts
  • Table 10: Mylan Inc.: key financials ($)
  • Table 11: Mylan Inc.: key financial ratios
  • Table 12: Sandoz International GmbH: key facts
  • Table 13: Teva Pharmaceutical Industries Limited: key facts
  • Table 14: Teva Pharmaceutical Industries Limited: key financials ($)
  • Table 15: Teva Pharmaceutical Industries Limited: key financial ratios

List of Figures

  • Figure 1: North America generics market value: $ billion, 2011-15(e)
  • Figure 2: North America generics market volume: % of total pharma volume, 2011-15(e)
  • Figure 3: North America generics market geography segmentation: % share, by value, 2015(e)
  • Figure 4: North America generics market value forecast: $ billion, 2015-20
  • Figure 5: North America generics market volume forecast: % of total pharma volume, 2015-20
  • Figure 6: Forces driving competition in the generics market in North America, 2015
  • Figure 7: Drivers of buyer power in the generics market in North America, 2015
  • Figure 8: Drivers of supplier power in the generics market in North America, 2015
  • Figure 9: Factors influencing the likelihood of new entrants in the generics market in North America, 2015
  • Figure 10: Factors influencing the threat of substitutes in the generics market in North America, 2015
  • Figure 11: Drivers of degree of rivalry in the generics market in North America, 2015
  • Figure 12: Allergan plc: revenues & profitability
  • Figure 13: Allergan plc: assets & liabilities
  • Figure 14: Mylan Inc.: revenues & profitability
  • Figure 15: Mylan Inc.: assets & liabilities
  • Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability
  • Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities
Back to Top